Evercore ISI raised the firm’s price target on Bausch + Lomb to $19 from $17 and keeps an In Line rating on the shares. In MedTech, utilization remains positive into Q3 and the capex outlook into the next year remains “healthy,” says Evercore. In life science tools, bioprocess trends for are on track for improvement in the second half, but the debate is around the instrument outlook and China stimulus given the recent run in stocks in the space, the analyst tells investors in MedTech and Tools Q3 preview.

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

See today’s best-performing stocks on TipRanks >>

Read More on BLCO:

• Bausch + Lomb Unveils New E-Commerce Platform, Opal

• Bausch + Lomb price target raised to $22 from $19 at H.C. Wainwright

• Bausch + Lomb price target raised to $19 from $16 at Stifel

• Bausch + Lomb moved to No Rating at BofA amid M&A reports

• Bausch + Lomb rises 7.9%